Cabozantinib
Treatment for Kidney Cancer
Typical Dosage: 60 mg oral once daily
Effectiveness
75%
Safety Score
30%
Clinical Trials
95
Participants
500
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
60 mg oral once daily
Time to Effect
Weeks to months
Treatment Duration
Until disease progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200,000
Monitoring:$20,000
Side Effect Mgmt:$10,000
Total Annual:$230,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$90,000/QALY
QALYs Gained
0.35
Outcome-Based Costs
Cost per Responder
$500,000
Cost per Remission
$5,750,000
Comparison vs Sunitinib
Cost Difference
+$110,000/year
More expensive
QALY Difference
+0.35 QALYs
Better outcomes
Dominance
No dominance
Active Clinical Trials
9 active trials recruiting for Cabozantinib in Kidney Cancer
Cabo-POLARIS : A Trial to Evaluate Cabozantinib Among Haemodialysied Patients
NCT05241561NOT YET RECRUITINGPHASE2
24 participants
INTERVENTIONAL
Besançon, France
Started: Jun 1, 2022
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
NCT04586231ACTIVE NOT RECRUITINGPHASE3
708 participants
INTERVENTIONAL
Chandler, United States +183 more
Started: Feb 25, 2021
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
NCT06934057RECRUITINGPHASE4
50 participants
INTERVENTIONAL
Angers, France +6 more
Started: May 16, 2025
Cabozantinib Dose Skipping as an Alternative to Dose Reductions
NCT07077161NOT YET RECRUITINGPHASE2
34 participants
INTERVENTIONAL
Started: Jan 1, 2026
Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma
NCT04416646ACTIVE NOT RECRUITING
100 participants
OBSERVATIONAL
Padua, Italy
Started: Feb 27, 2019
Retrospective Analysis of Patients With Metastatic Renal Cell Carcinoma Treated With CABOzantinib
NCT06548867RECRUITING
80 participants
OBSERVATIONAL
Reggio Emilia, Italy
Started: May 28, 2024
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
NCT06835972RECRUITINGPHASE1, PHASE2
43 participants
INTERVENTIONAL
Baltimore, United States +7 more
Started: Feb 14, 2025
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
NCT04022343ACTIVE NOT RECRUITINGPHASE2
22 participants
INTERVENTIONAL
Atlanta, United States
Started: Aug 6, 2019
Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer
NCT04823923RECRUITINGNA
60 participants
INTERVENTIONAL
Marseille, France +4 more
Started: Dec 6, 2021
Completed Clinical Trials
9 completed trials for Cabozantinib in Kidney Cancer
caBozantinib in cOllectiNg ductS Renal Cell cArcInoma
NCT03354884COMPLETEDPHASE2
23 participants
INTERVENTIONAL
Milan, Italy
Started: Jan 12, 2018
A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma
NCT03463681COMPLETEDPHASE2
49 participants
INTERVENTIONAL
Milan, Italy
Started: Jun 11, 2018
Study of Cabozantinib Efficacy, Safety and Tolerability in Metastatic Renal Carcinoma in Aged Fragile Patients: CABOMAYOR Study
NCT04134390COMPLETEDPHASE2
25 participants
INTERVENTIONAL
Ciudad Real, Spain +9 more
Started: Feb 17, 2020
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
NCT04338269COMPLETEDPHASE3
522 participants
INTERVENTIONAL
Tucson, United States +124 more
Started: Jul 28, 2020
Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
NCT04804813COMPLETED
388 participants
OBSERVATIONAL
Tokyo, Japan
Started: Mar 29, 2021
Spanish Real-World Evidence Cabozantinib
NCT04510688COMPLETED
275 participants
OBSERVATIONAL
Córdoba, Spain +31 more
Started: Oct 23, 2019
ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)
NCT03685448COMPLETEDPHASE2
35 participants
INTERVENTIONAL
Albury, Australia +10 more
Started: Apr 11, 2019
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases
NCT03967522COMPLETEDPHASE2
26 participants
INTERVENTIONAL
Angers, France +11 more
Started: Nov 29, 2019
Cabozantinib for Advanced Urothelial Cancer
NCT01688999COMPLETEDPHASE2
69 participants
INTERVENTIONAL
Bethesda, United States
Started: Sep 11, 2012
Showing 20 of 97 total trials